Conclusion
CYP2D6 genotype has a great impact on atomoxetine exposure, where our
real-world data suggest atomoxetine dose requirements to be around half
and one-tenth in CYP2D6 IM and PM vs. NM patients, respectively. When
adding CYP2C19 genotype as a factor of relevance for personalized
atomoxetine dosing, CYP2C19*2 carriers should further reduce the
dose by a third. These findings suggest that pre-emptive CYP2D6/CYP2C19
genotyping should be performed to individualize atomoxetine dosing and
prevent adverse effects.